Glenmark Pharmaceuticals Ltd (GLENMARK)
₹2,298.70
Mkt cap
₹64,875 Cr
P/E ratio
20.80
P/B
6.18
Div yield
0.22%
ROE
23.60%
ROCE
39.80%
EPS (TTM)
₹110.51
Book value
₹372
52W range
1,793–2,538
Sector
Healthcare
Price history
Previous close
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. [1]
NSE GLENMARKBSE 532296
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−9.41% from high₹2,299
₹1,793+28.23% from low₹2,538
Current
₹2,298.70
Prev close
₹2,339.00
Day
−1.72%
Price performance
1D
−1.72%
1W
+6.10%
1M
−5.85%
3M
+4.95%
6M
−4.77%
1Y
+24.21%
YTD
+11.34%
Financials
Revenue, profit & margin
P/E ratio
20.8×
GLENMARK is 39% below the sector median of 34.0×
GLENMARK20.8×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 | |
| Expenses | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 | |
| Operating Profit | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 | |
| OPM % | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% | |
| Other Income | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 | |
| Interest | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 | |
| Depreciation | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 | |
| Profit before tax | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 | |
| Tax % | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% | |
| Net Profit | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 | |
| EPS in Rs | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.10% · closed higher next day 20 of last 62
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23◦ | 14 Feb '24◦ | 24 May '24◦ | 14 Aug '24◦ | 15 Nov '24◦ | 14 Feb '25◦ | 23 May '25◦ | 14 Aug '25◦ | 14 Nov '25◦ | 30 Jan '26◦ | 29 May '26◦ | 31 Jul '26◦ |
| Earnings day | −6.87% | +1.64% | +8.06% | +5.00% | −3.13% | +3.84% | −2.12% | −3.46% | −1.41% | −4.74% | −3.24% | −0.17% |
| +1 day | −3.45% | +9.41% | +11.99% | +9.41% | −2.68% | +4.25% | −2.48% | −4.83% | −2.79% | −3.06% | −3.97% | −0.40% |
| +5 days | −0.03% | +14.46% | +13.53% | +13.11% | −0.80% | +0.16% | +5.44% | −4.33% | −2.81% | −2.06% | −4.33% | +0.78% |
| +15 days | +3.68% | +19.83% | +19.97% | +14.18% | +0.58% | +5.83% | +18.53% | +3.51% | +1.39% | +1.16% | −3.65% | +7.02% |
| +30 days | +9.97% | +23.81% | +31.18% | +13.04% | +5.27% | +16.79% | +30.97% | −4.49% | +7.08% | +6.45% | +1.33% | +6.17% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202646.65%Promoter
Promoters46.65%
FIIs21.51%0.62
DIIs17.63%0.97
Public14.17%0.36
Government0.04%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Glenmark Pharma. | ₹2,298.70 | 20.79 | 64,875 | 0.22% | 483 | +85.50% | 4,018 | +23.10% | 39.77% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts58
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025PPTJul 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Oct - Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Intimation of Earnings CallBoard Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of Glenmark Pharmaceuticals Limited ('The Company') For The Quarter And Half Year Ended September 30, 2026 23 Oct - Board meets November 5, 2026 to approve Q2 and half-year FY2026 unaudited financial results.Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Oct - Glenmark Therapeutics launches Adapalene Gel USP 0.1% OTC in new pump packs on October 6, 2026.Closure of Trading Window 28 SepAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 23 Sep - Glenmark received USFDA EIR for Goa facility on September 23, 2026, with VAI status.